NewAmsterdam Pharma is a clinical-stage company focused on the research and development of transformative therapies for cardio-renal diseases. It investigates Obicetrapib as an LDL-c lowering therapy for patients with statin intolerance or for patients with Arteriosclerotic Cardiovascular Disease/Familial Hypercholesterolemia (ASCVD/FH) on maximally-tolerated statin therapy.